Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 1/2020

01-02-2020 | Omeprazole | Research Article

The inappropriate use of proton pump inhibitors during admission and after discharge: a prospective cross-sectional study

Authors: Onuma Sattayalertyanyong, Premrutai Thitilertdecha, Chonticha Auesomwang

Published in: International Journal of Clinical Pharmacy | Issue 1/2020

Login to get access

Abstract

Background Proton pump inhibitors are often inappropriately prescribed during hospital admission and after discharge. The inappropriate prescription may be associated with increased and unnecessary healthcare costs. Objective To determine the prevalence of inappropriate prescription of proton pump inhibitors during hospital admission and after discharge at Thailand’s largest national tertiary referral center. Setting Medicine wards at Siriraj Hospital (Bangkok, Thailand) during September 2016 to September 2017. Method This prospective observational cross-sectional study in hospitalized patients who were prescribed, or who were already taking proton pump inhibitors. Medical records were reviewed to determine whether proton pump inhibitors were prescribed at discharge and at the 1-month follow-up. Main outcome measure Prevalence of inappropriate prescription of proton pump inhibitors during hospital admission and after discharge, indication of inappropriate prescription. Results Two hundred and sixty-five patients (mean age: 65.8 ± 18.3 years, 50.9% men) were included. Approximately half of patients had proton pump inhibitor treatment initiated in the hospital, and the other 50.6% started treatment earlier. Among all patients, 50.6% were inappropriately prescribed proton pump inhibitors, in which 79.1% resulted from invalid indications. Fifty-two percent and 47.3% of patients who were prescribed proton pump inhibitors at discharge and at the 1-month follow-up had no indications for them. Gastrointestinal ulcer prophylaxis in low-risk patients was the most commonly observed incorrect indication. Aspirin (p = 0.030) and corticosteroids (p = 0.038) were both found to be significantly associated with the inappropriate prescription of proton pump inhibitors. The estimated cost of inappropriate use among inpatients and outpatients was $118,659 and $214,663 per year, respectively. Conclusion Proton pump inhibitors are excessively and inappropriately prescribed during hospital admission and after discharge in Thailand. The cost of this overprescribing is excessive and needs to be controlled.
Literature
1.
go back to reference Ford AC, Moayyedi P. Current guidelines for dyspepsia management. Dig Dis. 2008;26(3):225–30.PubMed Ford AC, Moayyedi P. Current guidelines for dyspepsia management. Dig Dis. 2008;26(3):225–30.PubMed
2.
go back to reference Talley NJ, Vakil N. Practice parameters committee of the American College of G. Guidelines for the management of dyspepsia. Am J Gastroenterol. 2005;100(10):2324–37.PubMed Talley NJ, Vakil N. Practice parameters committee of the American College of G. Guidelines for the management of dyspepsia. Am J Gastroenterol. 2005;100(10):2324–37.PubMed
3.
go back to reference Lanza FL, Chan FK, Quigley EM. Practice parameters committee of the American College of G. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–38.PubMed Lanza FL, Chan FK, Quigley EM. Practice parameters committee of the American College of G. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–38.PubMed
4.
go back to reference Niaz SK, Quraishy MS, Taj MA, Abid S, Alam A, Nawaz AA, et al. Guidelines on gastroesophageal reflux disease. J Pak Med Assoc. 2015;65(5):532–41.PubMed Niaz SK, Quraishy MS, Taj MA, Abid S, Alam A, Nawaz AA, et al. Guidelines on gastroesophageal reflux disease. J Pak Med Assoc. 2015;65(5):532–41.PubMed
5.
go back to reference Mohebbi L, Hesch K. Stress ulcer prophylaxis in the intensive care unit. Bayl Univ Med Cent Proc. 2009;22(4):373–6. Mohebbi L, Hesch K. Stress ulcer prophylaxis in the intensive care unit. Bayl Univ Med Cent Proc. 2009;22(4):373–6.
6.
go back to reference Morneau KM, Reaves AB, Martin JB, Oliphant CS. Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel. J Manag Care Pharm. 2014;20(2):187–93.PubMed Morneau KM, Reaves AB, Martin JB, Oliphant CS. Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel. J Manag Care Pharm. 2014;20(2):187–93.PubMed
7.
go back to reference Villamanan E, Ruano M, Lara C, Suarez-de-Parga JM, Armada E, Alvarez-Sala R, et al. Reasons for initiation of proton pump inhibitor therapy for hospitalised patients and its impact on outpatient prescription in primary care. Rev Esp Enferm Dig. 2015;107(11):652–8.PubMed Villamanan E, Ruano M, Lara C, Suarez-de-Parga JM, Armada E, Alvarez-Sala R, et al. Reasons for initiation of proton pump inhibitor therapy for hospitalised patients and its impact on outpatient prescription in primary care. Rev Esp Enferm Dig. 2015;107(11):652–8.PubMed
8.
go back to reference Ahrens D, Behrens G, Himmel W, Kochen MM, Chenot JF. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract. 2012;66(8):767–73.PubMed Ahrens D, Behrens G, Himmel W, Kochen MM, Chenot JF. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract. 2012;66(8):767–73.PubMed
9.
go back to reference Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010;66(12):1265–71.PubMedPubMedCentral Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010;66(12):1265–71.PubMedPubMedCentral
10.
go back to reference Akram F, Huang Y, Lim V, Huggan PJ, Merchant RA. Proton pump inhibitors: are we still prescribing them without valid indications? Australas Med J. 2014;7(11):465–70.PubMedPubMedCentral Akram F, Huang Y, Lim V, Huggan PJ, Merchant RA. Proton pump inhibitors: are we still prescribing them without valid indications? Australas Med J. 2014;7(11):465–70.PubMedPubMedCentral
11.
go back to reference Haroon M, Yasin F, Gardezi SK, Adeeb F, Walker F. Inappropriate use of proton pump inhibitors among medical inpatients: a questionnaire-based observational study. JRSM Short Rep. 2013;4(8):1–6. Haroon M, Yasin F, Gardezi SK, Adeeb F, Walker F. Inappropriate use of proton pump inhibitors among medical inpatients: a questionnaire-based observational study. JRSM Short Rep. 2013;4(8):1–6.
12.
go back to reference Perwaiz MK, Posner G, Hammoudeh F, Schmidt F, Neupane N, Enriquez D, et al. Inappropriate use of intravenous PPI for stress ulcer prophylaxis in an inner city community hospital. J Clin Med Res. 2010;2(5):215–9.PubMedPubMedCentral Perwaiz MK, Posner G, Hammoudeh F, Schmidt F, Neupane N, Enriquez D, et al. Inappropriate use of intravenous PPI for stress ulcer prophylaxis in an inner city community hospital. J Clin Med Res. 2010;2(5):215–9.PubMedPubMedCentral
13.
go back to reference Shin S. Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: a retrospective chart review. Ther Clin Risk Manag. 2015;11:649–57.PubMedPubMedCentral Shin S. Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: a retrospective chart review. Ther Clin Risk Manag. 2015;11:649–57.PubMedPubMedCentral
14.
go back to reference Eid SM, Boueiz A, Paranji S, Mativo C, Landis R, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med. 2010;49(23):2561–8.PubMed Eid SM, Boueiz A, Paranji S, Mativo C, Landis R, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med. 2010;49(23):2561–8.PubMed
15.
go back to reference Martin-Echevarria E, Pereira Julia A, Torralba M, Arriola Pereda G, Martin Davila P, Mateos J, et al. Assessing the use of proton pump inhibitors in an internal medicine department. Rev Esp Enferm Dig. 2008;100(2):76–81.PubMed Martin-Echevarria E, Pereira Julia A, Torralba M, Arriola Pereda G, Martin Davila P, Mateos J, et al. Assessing the use of proton pump inhibitors in an internal medicine department. Rev Esp Enferm Dig. 2008;100(2):76–81.PubMed
16.
go back to reference Reid M, Keniston A, Heller JC, Miller M, Medvedev S, Albert RK. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med. 2012;7(5):421–5.PubMed Reid M, Keniston A, Heller JC, Miller M, Medvedev S, Albert RK. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med. 2012;7(5):421–5.PubMed
17.
go back to reference Sirivunnabood S, Barameerungsikul C. Proton pump inhibitors for stress ulcer prophylaxis in general wards. R Thai Air Force Med Gaz. 2011;57(2):1–5. Sirivunnabood S, Barameerungsikul C. Proton pump inhibitors for stress ulcer prophylaxis in general wards. R Thai Air Force Med Gaz. 2011;57(2):1–5.
18.
go back to reference Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017;37:19–24.PubMed Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017;37:19–24.PubMed
19.
go back to reference Parente F, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther. 2003;17(12):1503–6.PubMed Parente F, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther. 2003;17(12):1503–6.PubMed
20.
go back to reference Zink DA, Pohlman M, Barnes M, Cannon ME. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21(10):1203–9.PubMed Zink DA, Pohlman M, Barnes M, Cannon ME. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21(10):1203–9.PubMed
21.
go back to reference Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120–8.PubMed Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120–8.PubMed
22.
go back to reference Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk in PPI. Am J Gastroenterol. 2009;104(Suppl 2):S27–32.PubMed Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk in PPI. Am J Gastroenterol. 2009;104(Suppl 2):S27–32.PubMed
23.
go back to reference Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–60.PubMed Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–60.PubMed
24.
go back to reference Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784–90.PubMed Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784–90.PubMed
25.
go back to reference Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989–95.PubMed Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989–95.PubMed
26.
go back to reference Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209–18 (quiz 19).PubMed Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209–18 (quiz 19).PubMed
27.
go back to reference Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79(2):76–83.PubMed Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79(2):76–83.PubMed
28.
go back to reference Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.PubMed Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.PubMed
29.
go back to reference Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf. 2013;4(3):125–33.PubMedPubMedCentral Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf. 2013;4(3):125–33.PubMedPubMedCentral
30.
go back to reference Ladd AM, Panagopoulos G, Cohen J, Mar N, Graham R. Potential costs of inappropriate use of proton pump inhibitors. Am J Med Sci. 2014;347(6):446–51.PubMed Ladd AM, Panagopoulos G, Cohen J, Mar N, Graham R. Potential costs of inappropriate use of proton pump inhibitors. Am J Med Sci. 2014;347(6):446–51.PubMed
31.
go back to reference Freston JW. Review article: role of proton pump inhibitors in non-H pylori-related ulcers. Aliment Pharmacol Ther. 2001;15(Suppl 2):2–5.PubMed Freston JW. Review article: role of proton pump inhibitors in non-H pylori-related ulcers. Aliment Pharmacol Ther. 2001;15(Suppl 2):2–5.PubMed
32.
go back to reference Wilcox CM, Hirschowitz BI. Treatment strategies for Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2009;10(7):1145–57.PubMed Wilcox CM, Hirschowitz BI. Treatment strategies for Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2009;10(7):1145–57.PubMed
33.
go back to reference Bhatt DLSJ, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol. 2008;52(18):1502.PubMed Bhatt DLSJ, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol. 2008;52(18):1502.PubMed
34.
go back to reference Zeitoun A, Zeineddine M, Dimassi H. Stress ulcer prophylaxis guidelines: are they being implemented in Lebanese health care centers? World J Gastrointest Pharmacol Ther. 2011;2(4):27–35.PubMedPubMedCentral Zeitoun A, Zeineddine M, Dimassi H. Stress ulcer prophylaxis guidelines: are they being implemented in Lebanese health care centers? World J Gastrointest Pharmacol Ther. 2011;2(4):27–35.PubMedPubMedCentral
36.
go back to reference Monnig AA, Prittie JE. A review of stress-related mucosal disease. J Vet Emerg Crit Care (San Antonio). 2011;21(5):484–95. Monnig AA, Prittie JE. A review of stress-related mucosal disease. J Vet Emerg Crit Care (San Antonio). 2011;21(5):484–95.
37.
go back to reference Khalili H, Dashti-Khavidaki S, Hossein Talasaz AH, Tabeefar H, Hendoiee N. Descriptive analysis of a clinical pharmacy intervention to improve the appropriate use of stress ulcer prophylaxis in a hospital infectious disease ward. J Manag Care Pharm. 2010;16(2):114–21.PubMed Khalili H, Dashti-Khavidaki S, Hossein Talasaz AH, Tabeefar H, Hendoiee N. Descriptive analysis of a clinical pharmacy intervention to improve the appropriate use of stress ulcer prophylaxis in a hospital infectious disease ward. J Manag Care Pharm. 2010;16(2):114–21.PubMed
38.
go back to reference Elena R, Su HL, Alberto MB, Enrique P, Salvador F, Raul M, et al. Overuse of PPIs in patients at admission, during hospitalisation, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol. 2010;5(4):288–97. Elena R, Su HL, Alberto MB, Enrique P, Salvador F, Raul M, et al. Overuse of PPIs in patients at admission, during hospitalisation, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol. 2010;5(4):288–97.
39.
go back to reference van Vliet EPM, Otten HJAM, Rudolphus A, Knoester PD, Hoogsteden HC, Kuipers EJ, et al. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol. 2008;20(7):608–12.PubMed van Vliet EPM, Otten HJAM, Rudolphus A, Knoester PD, Hoogsteden HC, Kuipers EJ, et al. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol. 2008;20(7):608–12.PubMed
40.
go back to reference Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16(2):122–9.PubMed Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16(2):122–9.PubMed
41.
go back to reference Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83(975):66–8.PubMedPubMedCentral Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83(975):66–8.PubMedPubMedCentral
42.
go back to reference Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012;5(4):219–32.PubMedPubMedCentral Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012;5(4):219–32.PubMedPubMedCentral
Metadata
Title
The inappropriate use of proton pump inhibitors during admission and after discharge: a prospective cross-sectional study
Authors
Onuma Sattayalertyanyong
Premrutai Thitilertdecha
Chonticha Auesomwang
Publication date
01-02-2020
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 1/2020
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00955-8

Other articles of this Issue 1/2020

International Journal of Clinical Pharmacy 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.